No attachments available.
A--Drug Manufacturing and Formulation Program (DMFP)
Contact and place of performance
PLUGGE, RIEKA N
Menlo Park, CA
USA
Four (4) Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts with a maximum ordering value of $49,999,999.00 and an ordering period from May 4, 2026 through May 3, 2036, were awarded on May 4, 2026. Concurrently, the first task orders were issued to each awardee with an effective date of May 4, 2026 through July 3, 2026, in the firm-fixed price amount totaling $5,000.00.
The National Institutes of Health, National Institute on Drug Abuse (NIDA) awarded four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts under the Drug Manufacturing and Formulation Program (DMFP) on May 4, 2026. These awards carry a maximum total ordering value of $49,999,999.00 and an ordering period extending from May 4, 2026, through May 3, 2036. Simultaneously, the agency issued initial firm-fixed-price task orders to each awardee totaling $5,000.00, with a performance period effective from May 4, 2026, through July 3, 2026.
This requirement is classified under NAICS code 325412 for Pharmaceutical Preparation Manufacturing and PSC code AN11 for Health R&D Services; Health Care Services; Basic Research. There was no set-aside used for this procurement, designated as NONE; NONE. Primary work for this program is located in Menlo Park, California, under solicitation number 75N95024R00077. Rieka N. Plugge serves as the point of contact for this award notice.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.